News
Life Science

Structures of several clinically relevant NUDT15 variants are discovered – paving the way for better cancer treatments

Recent research by a group of researchers from Sweden, the US, and the UK successfully developed a specific NUDT15 inhibitor, TH7755, that helped the group to obtain structures of clinically relevant NUDT15 variants: Arg139Cys, Arg139His, Val18Ile, and V18_V19insGlyVal. These insights allow further understandings of the structural basis of thiopurine intolerance in patients carrying these NUDT15

Highlights

Drone image of MAX IV from above, surrounded by green landscape and the horizon.
MAX IV

A record year for research at MAX IV

MAX IV is making significant societal contributions in terms of record-high scientific productivity. In 2023, the number of publications increased by 51% compared to the previous year, and the number of unique users increased by 31%. Moreover, the number of proposals submitted in the most recent Open Call was higher than ever.

9y9a9159 2
Collaboration

Conceptual design for three potential new beamlines developed with WISE

After successfully bringing the first 16 funded beamlines into operation, we now look into the future. In collaboration with the Wallenberg Initiative Materials Science for Sustainability (WISE), funded by the Knut and Alice Wallenberg Foundation and together with the scientific community, MAX IV will develop the conceptual designs for three potential new materials science beamlines.